Mr. Swapan Kakumanu reports

NETRAMARK AND CAMH ANNOUNCE RESEARCH AWARD TO ADVANCE AI-DRIVEN DISCOVERY IN SCHIZOPHRENIA AND DEPRESSION

Netramark Holdings Inc., alongside the Centre for Addiction and Mental Health (CAMH) in Toronto, have been named recipients of the prestigious Ontario Research Fund -- Research Excellence (ORF-RE) Award.

The award recognizes innovative partnerships driving research excellence and technological advancement in Ontario. Under this collaboration, NetraAI, Netramark's mathematically augmented machine learning platform, will be deployed within CAMH's secure high performance computing environment to analyze genetic and epigenetic data from schizophrenia and major depressive disorder studies supported by the ORF-RE program.

The initiative aims to identify explainable patient subpopulations that clarify biological subtypes in psychiatric disorders and support next-generation precision treatment strategies. This research will also enhance NetraAI capabilities to serve pharmaceutical sponsors in the psychiatric space to improve their clinical trial outcomes.

Installation of the NetraAI software on CAMH's research cluster is being conducted by CAMH's research IT team with on-site support from Netramark. All analyses will use deidentified patient data, ensuring strict adherence to CAMH's data privacy and network security standards.

Dr. James Kennedy, head of the Tanenbaum Centre for pharmacogenetics at CAMH, said:

"This collaboration integrates Netramark's unique AI approach with CAMH's deep genomic and clinical data sets to explore how genetic and epigenetic patterns influence treatment response. The insights generated will advance our understanding of the genes that alter a patient's response to psychiatric medication. This will enable physicians to personalize treatment for each individual patient living with complex mental health illnesses such as schizophrenia or depression."

Dr. Joseph Geraci, founder and chief scientific and technology officer of Netramark, added:

"It makes me proud to have my work recognized through this award and to collaborate with CAMH, an internationally recognized institute for its leadership in psychiatric research. Combining their data sets with NetraAI's unique explainable AI framework allows us to uncover biologically grounded subpopulations that have previously eluded traditional analytics. We believe this work will contribute to next-generation precision medicine approaches for mental health and to also improve clinical trial outcomes."

The collaboration also includes evaluation of an additional "bonus data set" of Ontario Health Insurance Plan (OHIP) administrative data to enable cost-effectiveness analyses and explore the broader health system impact of personalized patient care.

About the Centre for Addiction and Mental Health (CAMH)

The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital and a world leading research centre in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto and is a Pan American Health Organization/World Health Organization Collaborating Centre.

About NetraAI

In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small data sets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to overfitting which drowns out critical information that could have been used to improve a trial's chance of success.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence (Gen AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.